海正药业(600267) - 2023 Q3 - 季度财报
HISUNHISUN(SH:600267)2023-10-27 16:00

Financial Performance - The company's operating revenue for Q3 2023 was ¥2,640,792,348.68, a decrease of 12.18% compared to ¥3,007,219,050.77 in the same period last year[6]. - Net profit attributable to shareholders for Q3 2023 reached ¥37,685,741.60, representing a significant increase of 210.03% from ¥12,077,611.96 in the previous year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥35,432,815.14, down 51.79% from ¥73,412,451.46 in the same period last year[6]. - Basic earnings per share for Q3 2023 was ¥0.02, a 100% increase from ¥0.01 in the same period last year[6]. - Diluted earnings per share for Q3 2023 was ¥0.06, up 200% from ¥0.02 in the previous year[6]. - Total revenue for the first three quarters of 2023 was approximately ¥8.70 billion, slightly down from ¥8.74 billion in the same period of 2022, representing a decrease of 0.5%[43]. - Operating profit for the first three quarters of 2023 increased to approximately ¥629.07 million, compared to ¥490.84 million in 2022, marking an increase of 28.2%[44]. - Net profit attributable to shareholders for the first three quarters of 2023 was approximately ¥457.10 million, up from ¥331.16 million in 2022, reflecting a growth of 37.9%[44]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥18,147,092,176.51, a decrease of 3.39% from ¥18,777,887,149.36 at the end of the previous year[12]. - The total non-current assets amount to ¥11,534,024,737.59, a decrease from ¥12,375,435,744.47, indicating a decline of about 6.81%[31]. - Total liabilities decreased to approximately ¥9.29 billion in 2023 from ¥10.45 billion in 2022, a reduction of 11.1%[41]. - The total equity attributable to shareholders increased to approximately ¥8.59 billion in 2023 from ¥8.08 billion in 2022, representing a growth of 6.3%[43]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥1,321,050,228.79, a decrease of 10.59% compared to ¥1,477,548,911.76 in the previous year[6]. - The cash inflow from operating activities showed improvement, contributing positively to the overall financial health of the company[47]. - In the first three quarters of 2023, the cash inflow from operating activities reached ¥9,405,878,053.19, an increase from ¥9,230,025,413.33 in the same period of 2022, representing a growth of approximately 1.9%[51]. - The net cash flow from operating activities for the first three quarters of 2023 was ¥1,321,050,228.79, down from ¥1,477,548,911.76 in 2022, indicating a decrease of about 10.6%[51]. - The total cash outflow from operating activities was ¥8,084,827,824.40, compared to ¥7,752,476,501.57 in the previous year, reflecting an increase of approximately 4.3%[51]. - The cash inflow from investment activities was ¥90,743,635.21, significantly lower than ¥422,926,016.04 in the same period last year, marking a decline of about 78.6%[51]. - The net cash flow from investment activities was -¥340,411,902.81, compared to -¥106,548,026.16 in 2022, indicating a worsening of approximately 219.5%[51]. - The cash inflow from financing activities totaled ¥2,670,152,438.58, down from ¥4,253,208,022.78 in the previous year, a decrease of about 37.2%[53]. - The net cash flow from financing activities was -¥764,636,081.12, an improvement from -¥1,453,065,237.63 in 2022, showing a reduction of approximately 47.4%[53]. - The cash and cash equivalents at the end of the period amounted to ¥1,384,570,397.71, an increase from ¥1,098,410,681.57 at the end of the same period last year, representing a growth of about 26%[53]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 55,953, with Zhejiang Haizheng Group Co., Ltd. holding 320,783,590 shares, accounting for 26.56%[21]. - The company has a total of 320,783,590 shares held by its largest shareholder, Zhejiang Haizheng Group Co., Ltd., which is a state-owned entity[21]. Research and Development - Research and development expenses for the first three quarters of 2023 were approximately ¥311.94 million, an increase from ¥286.40 million in 2022, indicating a rise of 8.9%[43]. Strategic Outlook - The company has not reported any significant new strategies or product developments in the current quarter[39]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[43].